

mGem: Sepsis and antimicrobial resistance in the context of advanced HIV disease

Rachel M. Wake,^{1,2} Nelesh P. Govender^{1,2,3,4}

AUTHOR AFFILIATIONS See affiliation list on p. 6.

ABSTRACT Sepsis triggered by bloodstream infections (BSI) is a significant driver of HIV-related mortality, particularly among in-patients with advanced HIV disease (AHD). Currently, the incidence, etiology, and outcomes of BSI in this population are poorly defined. We review the existing evidence, which shows an increased risk of BSI, particularly with antimicrobial-resistant (AMR) organisms, and higher BSI-associated mortality in patients with AHD. Causative bacterial and fungal pathogens are often unknown, but when identified, limited data show etiology has shifted probably owing to increasing coverage of antiretroviral treatment, antimicrobial prophylaxis, and rising global AMR trends. Further research is crucial to design and refine interventions before, during, and after hospital admission to reduce sepsis-related mortality in patients with AHD.

KEYWORDS human immunodeficiency virus, AIDS, sepsis, bloodstream infections, antimicrobial resistance

People with advanced HIV disease (AHD; defined among adults as a CD4 cell count <200 cells/ μ L or a World Health Organization [WHO] stage 3 or 4 clinical event) are at increased risk of hospitalization and death (1–4). Around 630,000 HIV-related deaths occurred in 2023, many among inpatients (5). HIV-related mortality rates remain high despite a widespread roll-out of antiretroviral therapy (ART).

Although signs of sepsis (the host-immune response to infection) are common among seriously ill people with AHD admitted to the hospital, the etiology and contribution of sepsis to mortality are poorly understood in this population. Some HIV-related deaths occur at home, particularly in lower resource settings with more limited access to healthcare (6). When healthcare is sought, multiple factors including frequent use of empirical broad-spectrum antibiotics paired with limited microbiological investigation mean that the causative pathogens of terminal sepsis events are often unknown.

In this short review, we seek to summarize the existing evidence and highlight the knowledge gaps regarding sepsis in the context of AHD, with a focus on bloodstream infections (BSI). Specifically, we will discuss the bacterial and fungal etiology of BSI, possible causes of culture-negative sepsis, and the burden of antimicrobial resistance (AMR) in this population. We consider the implications of these findings on future research priorities to delineate a refined package of interventions to reduce HIV-related mortality associated with sepsis.

AHD IS A PERSISTENT PROBLEM, PARTICULARLY IN AFRICAN COUNTRIES

A persistently high proportion of people living with HIV engage or re-engage in health services when they already have AHD. In 2015, this proportion was estimated to be 40% (33%–47%) in low- and middle-income countries (LMICs) and 29% (24%–34%) in high-income countries (HICs) (7). Recent data found this proportion to remain at

Editor Marcio Rodrigues, Instituto Carlos Chagas, Curitiba, Brazil

Address correspondence to Rachel M. Wake, rwake@sgul.ac.uk.

The authors declare no conflict of interest.

See the funding table on p. 6.

Published 11 April 2025

Copyright © 2025 Wake and Govender. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

around a third (32%–36%) across all income settings (8). However, the burden is largely shouldered by African countries, where an estimated 1.9 million (1.6–2.2 million) people with AHD are living (9). Furthermore, there is a higher mortality risk associated with AHD in LMICs compared to HICs (2). Targeted approaches to address sepsis and AMR among patients with AHD must, therefore, be adapted to the setting, with a particular need to optimize care in LMICs, in order to significantly reduce HIV-related mortality.

AHD DRIVES SEPSIS-RELATED ADMISSIONS

In LMICs with generalized epidemics, HIV is a major driver of hospitalization; people living with HIV make up 19%–46% of inpatients (10–13) and 39%–97% of these inpatients with HIV have AHD (4, 10, 11). Many of these admissions are related to severe infections. An inpatient trial (excluding those with known TB) in South Africa and Malawi documented WHO danger signs, indicating sepsis, in a fifth of patients with HIV at the time of admission (14). A meta-analysis of 99 studies from 2007 to 2014 across 50 countries revealed that AIDS-related illnesses (46%; 95% confidence interval [CI], 40%–53%) and bacterial infections (31%; 95% CI, 20%–42%) were the leading causes of admission among adults living with HIV (15). An updated meta-analysis of 110 studies from 2014 to 2023 revealed that despite greater ART coverage, AIDS-related illnesses and bacterial infections remain the most common causes of admission in 42% of cases (R. M. Burke et al., unpublished data). Sepsis is associated with a higher risk of death in patients with HIV (16), around a fifth of whom die during hospital admission (15). This is more than twice the odds of in-hospital death compared to HIV-seronegative individuals (pooled OR 2.6; 95% CI, 1.8–3.7), with a further 14% of deaths occurring during the year following discharge (2). Lower CD4 counts are associated with a greater risk of hospitalization, in-hospital, and post-discharge mortality as well as re-hospitalization (1, 3, 4, 13, 17).

AHD-RELATED SEPSIS IS UNDER-DIAGNOSED AND POORLY UNDERSTOOD

The contribution of sepsis to AHD deaths is challenging to decipher. Even among trial participants for whom causes of death are scrutinized by expert panels with access to extensive clinical information including verbal autopsy data, causal attribution is not always possible (6, 18). In the REALITY trial, 39% (88/225) of deaths were of unknown causes (6). However, since the trial intervention of enhanced antimicrobial prophylaxis reduced deaths that occurred with unknown cause (6% vs. 3.8%, $P = 0.03$), it is likely that a majority of these deaths were caused by infections. Among the 14.6% (33/225) of patients who were thought to have a bacterial infection as their primary cause of death, 14/33 (42%) had presumed BSI but with no organism identified; 10/33 (30%) were not investigated for infective etiology prior to death; and only one causative bacterial organism was identified in the remaining 23 patients (6). Autopsy studies confirm that severe bacterial infections are an underestimated cause of sepsis-related death among people with AHD. Autopsies of 39 adults with HIV in South Africa found a bacterial infection to be the most common primary cause of death in 13 cases (33%) and contributing to death in a further 17 (44%) (19). Another minimally invasive autopsy study of 34 adults with CD4 counts of ≤ 150 cells/ μL in South Africa found evidence of bacterial infection in 23 cases (68%) (20). Strikingly, a majority of bacterial pathogens identified at autopsy were not diagnosed by routine testing prior to death.

BACTERIAL BLOODSTREAM INFECTIONS

People living with HIV are at greater risk of bacterial BSI compared to individuals without HIV (21–24). In a rural Ugandan cohort, people with HIV were around 30 times more likely to be diagnosed with a bacterial BSI, with an incidence sevenfold higher in those with CD4 cell counts < 200 cells/ μL (21). A meta-analysis of community-onset BSI among hospitalized patients with fever in African and Asian countries found that 27% (676/2,513) participants with HIV had a BSI at admission compared to 10% (566/5,596)

of those without HIV (OR, 3.2 [95% CI, 2.8–3.7]). The odds of BSI with non-typhoidal *Salmonella enterica* (NTS) (OR 11.2 [95% CI, 5.9–21.6, $P < 0.001$]) and *Streptococcus pneumoniae* (OR 1.8 [95% CI, 1.0–3.1, $P = 0.04$]) were significantly increased in patients living with HIV compared to those without HIV but were not increased for other bacteria, *Escherichia coli*, *Staphylococcus aureus*, or *Salmonella Typhi* (22).

Expanding use of ART and primary antibiotic prophylaxis has likely led to a reduction in incidence and a shift in species distribution of bacterial BSI occurring in patients with HIV, though recent data are lacking (25, 26). In a systematic review including six studies documenting the impact of ART, rate ratios of bacterial BSIs following ART introduction ranged from 0.02 (95% CI, 0.01–0.04) in Zimbabwe to 0.63 (95% CI, 0.18–2.29) in Italy (24). In the pre-ART era, increased susceptibility to NTS was well described in people with AHD, likely related to high rates of transmission and associated malaria in countries shouldering the greatest HIV burden together with the failure of cell-mediated immunity to clear intracellular pathogens (27). While NTS and *S. pneumoniae* remain important in the post-ART era (21, 23, 28), other bacterial pathogens are increasingly common causes of sepsis (26, 29). Retrospective surveillance of BSIs among people with HIV in Spain noted an increase in the proportion caused by *E. coli* (7%–14%, $P = 0.004$) corresponding to a decrease in *Salmonella* spp. (21%–10%, $P = 0.01$) following the roll-out of ART (30). In France, a shift from *S. pneumoniae* to Enterobacterales as the main causative organisms of BSI has been documented among patients with HIV (26). In Italy, recent observational studies have revealed *E. coli* to be the most common cause, followed by *Staphylococcus* spp (29, 31). *S. aureus* is a common cause of BSI among people with HIV in Europe, Asia, and the United States, compared to African countries (24), probably related to overlapping risk factors of intravenous drug use and HIV infection in the former regions. In a study comparing causes of BSI between 1997/1998 and 2009/2010 in a single center in Malawi in which 90% of patients were living with HIV, the proportion of blood cultures yielding NTS declined from 6% to 4% ($P < 0.005$) though NTS remained the most common cause of BSI in 84/229 (37%) of cases (25). More recent data describing the impact of ART on the etiology of bacterial BSI among people with HIV in resource-limited settings are due.

In addition to the impact of ART and co-trimoxazole prophylaxis, the shift away from community-acquired pathogens may reflect improvements in survival among patients admitted to the hospital, who are then at risk of healthcare-associated (including line-related) bacterial infections. For example, the mortality rate associated with cryptococcal meningitis has reduced during past decades, leading to longer durations of inpatient care and intravenous treatment. Bacterial BSIs were found to be a major cause of death in study cohorts in Uganda and South Africa during 2010–2013, with 20% of patients developing a febrile illness associated with a positive blood culture at a median of 14 days (interquartile range 9–17) after admission. A majority of causative organisms were methicillin-resistant *S. aureus* (MRSA) and extended-spectrum beta-lactamase-producing *K. pneumoniae* (32). Using the WHO-recommended single-dose liposomal amphotericin B regimen, a shorter duration of hospitalization and intravenous therapy is likely to reduce the incidence of healthcare-associated BSI during the treatment of cryptococcal meningitis (33).

MYCOBACTERIAL BLOODSTREAM INFECTIONS

Disseminated mycobacterial infection is a common and probably under-recognized cause of sepsis among patients with AHD. Isolation of *Mycobacterium* spp. in culture from blood is enhanced by lysis-centrifugation to release intracellular organisms and specialized media to provide optimal growth conditions, for example, using Myco/F Lytic culture vials (Becton Dickinson Biosciences). Detection of mycobacterial bloodstream infections may, therefore, be limited by a lack of laboratory resources in LMICs which have the greatest burden of AHD (23). Among 22 studies included in a meta-analysis of community-acquired BSI in African countries, only 5 used specific mycobacterial blood culture techniques (23). In these five studies, *M. tuberculosis* was the most common

pathogen comprising over a third of all bloodstream isolates. When lysis-centrifugation is used, mycobacterial bloodstream infections have been found to be 23–25 times more likely in patients with HIV than in those without HIV (22, 23), occurring in 9%–24% of febrile inpatients with HIV (16, 34–38).

The proportion of BSIs caused by different *Mycobacterium* spp. varies geographically. While *M. avium* complex is relatively more common in Europe and the United States, *M. tuberculosis* predominates in African countries, causing 84.1% of mycobacterial BSI, compared to 11.4% caused by *M. avium* complex (22). In contrast, a study in Bangkok found *M. avium* complex (13.1%) to cause a similar proportion of BSI to *M. tuberculosis* (14.8%).

Patients with HIV and mycobacterial BSIs have lower median CD4 cell counts, higher HIV RNA viral loads, and are more likely to die during hospital admission with sepsis than other patients with HIV, including those with bacterial BSI. In-hospital mortality is estimated to occur in around 50% of patients (34).

FUNGAL BLOODSTREAM INFECTIONS


Similarly, the contribution of fungal pathogens (*Candida* spp., *Cryptococcus* spp., and endemic fungi) to sepsis in patients with HIV is likely underestimated due to limited diagnostic capabilities and lack of clinical suspicion. Invasive fungal infections are associated with lower CD4 cell counts (39, 40) and increased mortality risk in patients with HIV (40, 41). Meta-analyses in African and Asian countries found up to 70 cases of fungal BSI with *Cryptococcus* spp., *Histoplasma* spp., and *Talaromyces* spp. to occur exclusively in people with HIV (22, 23). Lysis-centrifugation may optimize the culture of some fungi. In Vietnam, Myco/F lytic blood cultures in addition to fungal antigen testing diagnosed invasive mycoses in 27.3% of hospitalized patients with AHD (*Talaromyces* spp. [19.8%], *Cryptococcus* spp. [4.7%], and *Histoplasma* spp. [2.9%]) (38).

While cryptococcal BSI frequently occurs in patients with HIV-associated cryptococcal meningitis, it has also been reported in 16% (11/67) of patients with cryptococcal antigenemia but without symptoms or signs of meningitis, using standard blood cultures (42). The clinical implications and optimal treatment approach for cryptococcal BSI in the absence of meningitis are unclear, though guidelines currently recommend the same treatment as for meningitis.

CULTURE-NEGATIVE SEPSIS

Diagnosis of BSI is highly variable and dependent on multiple factors including health-seeking behaviors, blood culture utilization, sampling practices, timing of empirical antibiotics, and laboratory limitations such as the use of less-sensitive manual blood culture systems. Differences are not only related to health expenditure. Blood culture utilization is found to vary across Southeast Asian countries with similar spending per capita (43). A study from 61 hospitals in African countries, most of which had on-site microbiology laboratories, found underutilization secondary to factors including user fees, power cuts, and water shortages (44). Additionally, sampling volumes, sampling technique, and timing affect diagnostic yield. For example, using 2 mL rather than the recommended 10 mL blood reduces the sensitivity of blood cultures for *S. Typhi* to 0.51 (95% CI, 0.44–0.57) (45). Differing blood culture utilization and practices will impact epidemiological, etiological, and AMR surveillance data, necessitating the use of sentinel syndromic surveillance strategies (46, 47). However, in routine care, this means a minority of patients hospitalized with sepsis are likely to be diagnosed with a BSI.

Furthermore, in the context of AHD, sepsis may be driven by the reactivation and dysregulated replication of viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), and human herpesvirus 8 (HHV8) or infection with fastidious pathogens, e.g., *Bartonella* spp. Serological studies confirm that HIV is associated with higher rates of *Bartonella* infection (48) found to be prevalent (using whole blood PCR or serum IgG assays) in around a fifth of patients living with HIV (49, 50).



- Patients entering/ re-entering HIV care require CD4 testing - counts fluctuate due to ART non-adherence and co-infections.
- Enhanced screening and diagnostic packages based on presenting syndrome might include, for example, TB PCR on urine samples, histoplasma antigen testing and mycobacterial blood cultures. Screening may need to be repeated if patients re-enter care.
- Prophylactic, empirical and definitive antimicrobial regimens for patients with AHD should be informed by clinical trials, and comprehensive aetiological and epidemiological data including local AMR burden.
- Patients with AHD may benefit from peer support, particularly those who disengage and re-enter care and following hospital discharge. Cognitive assessment is important to identify those who would benefit from tailored assistance for ART/antimicrobial treatment adherence.

FIG 1 Refined interventions for the prevention and treatment of AHD-related sepsis. Created in BioRender (<https://BioRender.com/l88m097>).

Molecular or sequencing techniques can reveal a fuller picture of the prominent infective causes of sepsis in the context of AHD. A 43-target multiplex PCR assay detected potentially causative bacterial, fungal, viral, and parasitic organisms in 85% (207/245) patients with AHD admitted to hospital with sepsis in Uganda, while blood cultures were only positive in 47% (51).

ANTIMICROBIAL RESISTANCE AND AHD

Patients with AHD may be disproportionately affected by the global AMR crisis due to increased exposure to healthcare settings, antimicrobials, and other ill-defined host-pathogen interactions. A meta-analysis of 92 studies of AMR bacterial infections (around half in LMICs) found people with HIV had increased odds of MRSA colonization (OR 2.12, 95% CI, 1.36–3.30), infection with *S. pneumoniae* with reduced penicillin susceptibility (OR 2.28, 95% CI, 1.75–2.97), and third-generation cephalosporin-resistant *E. coli*/*K. pneumoniae* (OR 1.59, 95% CI, 0.83–3.05) (52). Increasing co-trimoxazole resistance was observed from 1997/1998 to 2009/2010 in Malawi, rising to 87% (73/84) of NTS and 95% (54/57) *S. pneumoniae* isolates. Patients taking co-trimoxazole were seven times more likely (95% CI, 1.6–31.2) to have a BSI with a co-trimoxazole-resistant organism (25). In a large cohort of >7,000 patients with HIV in France (2000–2017), co-trimoxazole

prophylaxis was associated with a greater risk of non-susceptibility to other antibiotics as well as to co-trimoxazole in *S. pneumoniae* and Enterobacterales (26).

APPROACHES TO AHD-RELATED SEPSIS

Effective approaches to the prevention and treatment of AHD-related sepsis are key to reducing HIV deaths. These must be focused on LMICs, where the burden of AHD is greatest. Although the current WHO package of care for people with AHD (53) is evidence-based, interventions are insufficient for sepsis prevention, incompletely implemented, and focused on outpatient settings. Furthermore, since patients with AHD are more likely to cycle in-and-out of care (54) (with corresponding CD4 fluctuations), a single entry point to AHD-targeted screening is inappropriate. Optimized approaches must be considered and prioritized for research (see Fig. 1). This includes expanding screening and prophylactic antimicrobial regimens to cover diseases beyond those currently targeted (i.e. cryptococcal antigenaemia, active and latent tuberculosis (TB), and *Pneumocystis jirovecii* pneumonia (PCP)), application of tailored diagnostic algorithms and locally-informed empirical treatment regimens for patients with AHD admitted to hospital with sepsis, and enhanced programs to capture individuals as they enter or re-enter care with AHD, focusing on post-discharge support. Designing such a refined package of interventions to prevent AIDS-related deaths requires focused research investment. Clinical trial evidence, such as from the randomized-controlled REVIVE trial of azithromycin prophylaxis (NCT05580666), will be essential to inform guidelines and policy. Additionally, comprehensive region-specific data regarding the incidence and etiology of sepsis and sepsis-related death, as well as the relative frequency of AMR pathogens in this population, are urgently required to inform effective strategies.

ACKNOWLEDGMENTS

N.P.G. was supported by the National Institute for Health and Care Research (NIHR; grant numbers NIHR134342 and NIHR303140) with UK international development funding from the UK Government to support global health research. R.M.W. was also supported through NIHR303140. The views expressed in this article are those of the authors and not necessarily those of the NIHR or the UK Government. This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation (grant number: INV077442). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.

AUTHOR AFFILIATIONS

¹Wits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

²Institute for Infection and Immunity, City-St George's University of London, London, England, United Kingdom

³MRC Centre for Medical Mycology, University of Exeter, Exeter, England, United Kingdom

⁴Division of Medical Microbiology, Faculty of Health Sciences, University of Cape Town, Rondebosch, Western Cape, South Africa

AUTHOR ORCIDs

Rachel M. Wake  <http://orcid.org/0000-0003-3193-4888>

Nelesh P. Govender  <http://orcid.org/0000-0001-7869-9462>

FUNDING

Funder	Grant(s)	Author(s)
National Institute for Health and Care Research	NIHR 134342	Nelesh P. Govender
National Institute for Health and Care Research	NIHR 303140	Rachel M. Wake

Funder	Grant(s)	Author(s)
		Nelesh P. Govender
Bill and Melinda Gates Foundation	INV077442	Rachel M. Wake

AUTHOR CONTRIBUTIONS

Rachel M. Wake, Conceptualization, Funding acquisition, Writing – original draft, Writing – review and editing | Nelesh P. Govender, Conceptualization, Funding acquisition, Writing – review and editing

REFERENCES

- Nijhawan AE, Clark C, Kaplan R, Moore B, Halm EA, Amarasingham R. 2012. An electronic medical record-based model to predict 30-day risk of readmission and death among HIV-infected inpatients. *J Acquir Immune Defic Syndr* 61:349–358. <https://doi.org/10.1097/QAI.0b013e31826ebc83>
- Ford N, Patten G, Rangaraj A, Davies M-A, Meintjes G, Ellman T. 2022. Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis. *Lancet HIV* 9:e150–e159. [https://doi.org/10.1016/S2352-3018\(21\)00329-5](https://doi.org/10.1016/S2352-3018(21)00329-5)
- Meyer-Rath G, Brennan AT, Fox MP, Modisenyane T, Tshabangu N, Mohapi L, Rosen S, Martinson N. 2013. Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa. *J Acquir Immune Defic Syndr* 62:322–328. <https://doi.org/10.1097/QAI.0b013e31827e8785>
- Ousley J, Niyibizi AA, Wanjala S, Vandenbulcke A, Kirubi B, Omwoyo W, Price J, Salumu L, Szumilin E, Spiers S, van Cutsem G, Mashako M, Mangana F, Moudarichirou R, Harrison R, Kalwangila T, Lumowo G, Lambert V, Maman D. 2018. High proportions of patients with advanced HIV are antiretroviral therapy experienced: hospitalization outcomes from 2 sub-Saharan African sites. *Clin Infect Dis* 66:S126–S131. <https://doi.org/10.1093/cid/ciy103>
- UNAIDS. 2022. UNAIDS global AIDS update. UNAIDS 2022 report. Available from: <https://indanger.unaids.org>
- Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugenyi P, Prendergast AJ, Walker AS, Gibb DM, REALITY Trial Team. 2017. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. *N Engl J Med* 377:233–245. <https://doi.org/10.1056/NEJMoa1615822>
- leDEA and COHERE Cohort Collaborations. 2018. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. *Clin Infect Dis* 66:893–903. <https://doi.org/10.1093/cid/cix915>
- Ford N, Kassanjee R, Stelzle D, Jarvis JN, Sued O, Perrin G, Doherty M, Rangaraj A. 2025. Global prevalence of advanced HIV disease in healthcare settings: a rapid review. *J Int AIDS Soc* 28:e26415. <https://doi.org/10.1002/jia2.26415>
- Stelzle D, Rangaraj A, Jarvis JN, Razakasoa NH, Low-Beer D, Doherty M, Ford N, Dalal S. 2024. High prevalence of advanced HIV disease in sub-Saharan Africa: an analysis of 11 household surveys (abstract 196). CROI Conference; Denver, CO. <https://www.croiconference.org/abstract/high-prevalence-of-advanced-hiv-disease-in-sub-saharan-africa-an-analysis-of-11-household-surveys>
- Owachi D, Akatukunda P, Nanyanzi DS, Katwesigye R, Wanyina S, Muddu M, Kawuma S, Kalema N, Kabugho C, Semitala FC. 2024. Mortality and associated factors among people living with HIV admitted at a tertiary-care hospital in Uganda: a cross-sectional study. *BMC Infect Dis* 24:239. <https://doi.org/10.1186/s12879-024-09112-7>
- Yudelowitz G, Ive P, Fox M. 2021. An audit of HIV-infected patients admitted to Helen Joseph hospital in Johannesburg, South Africa. *Wits J Clin Med* 3:189–196. <https://doi.org/10.18772/26180197.2021.v3n3a6>
- Klinger AE, Kronen RJ, Barak T, Mophuthegi P, Makhema J, Zash R, Shapiro R. 2020. Mortality among inpatients after the initiation of “treat all” with dolutegravir in Botswana. *Open Forum Infect Dis* 7:S429–S429. <https://doi.org/10.1093/ofid/ofaa439.959>
- Barak T, Neo DT, Tapela N, Mophuthegi P, Zash R, Kalenga K, Perry ME, Malane M, Makhema J, Lockman S, Shapiro R. 2019. HIV - associated morbidity and mortality in a setting of high ART coverage: prospective surveillance results from a district hospital in Botswana. *J Intern AIDS Soc* 22:e25428. <https://doi.org/10.1002/jia2.25428>
- Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, Peters JA, Chiume L, Flach C, Lawn SD, Fielding K. 2018. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. *Lancet* 392:292–301. [https://doi.org/10.1016/S0140-6736\(18\)31267-4](https://doi.org/10.1016/S0140-6736(18)31267-4)
- Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, Davies M-A, Vitoria M, Penazzato M, Nsanzimana S, Frigati L, O'Brien D, Ellman T, Ajose O, Calmy A, Doherty M. 2015. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. *Lancet HIV* 2:e438–e444. [https://doi.org/10.1016/S2352-3018\(15\)00137-X](https://doi.org/10.1016/S2352-3018(15)00137-X)
- Silva JM Jr, dos Santos SDS. 2013. Sepsis in AIDS patients: clinical, etiological and inflammatory characteristics. *J Int AIDS Soc* 16:17344. <https://doi.org/10.7448/IAS.16.1.17344>
- Burke RM, Henrion MYR, Mallewa J, Masamba L, Kalua T, Khundi M, Gupta-Wright A, Rylance J, Gordon SB, Masasa C, Corbett EL, Mwandumba HC, Macpherson P. 2021. Incidence of HIV-positive admission and inpatient mortality in Malawi (2012–2019). *AIDS* 35:2191–2199. <https://doi.org/10.1097/QAD.0000000000003006>
- Karat AS, Tlali M, Fielding KL, Charalambous S, Chihota VN, Churchyard GJ, Hanifa Y, Johnson S, McCarthy K, Martinson NA, Omar T, Kahn K, Chandramohan D, Grant AD. 2017. Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: comparing verbal autopsy, minimally-invasive autopsy, and research data. *PLoS One* 12:e0174097. <https://doi.org/10.1371/journal.pone.0174097>
- Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, Martinson NA, Bangsberg DR, Venter WDF. 2012. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. *PLoS One* 7:e47542. <https://doi.org/10.1371/journal.pone.0047542>
- Karat AS, Omar T, von Gottberg A, Tlali M, McCarthy K, Wolter N, Wong EB, Charalambous S, Grant AD. 2016. Autopsy prevalence of tuberculosis and other potentially treatable infections among adults with advanced HIV enrolled in out-patient care in South Africa. *PLoS One* 11:e0166158. <https://doi.org/10.1371/journal.pone.0166158>
- Mayanja BN, Todd J, Hughes P, Van der Paal L, Mugisha JO, Atuhumuza E, Tabuga P, Maher D, Grosskurth H. 2010. Septicaemia in a population-based HIV clinical cohort in rural Uganda, 1996–2007: incidence, aetiology, antimicrobial drug resistance and impact of antiretroviral therapy. *Trop Med Int Health* 15:697–705. <https://doi.org/10.1111/j.1365-3156.2010.02528.x>
- Marchello CS, Dale AP, Pisharody S, Rubach MP, Crump JA. 2019. A systematic review and meta-analysis of the prevalence of community-onset bloodstream infections among hospitalized patients in Africa and Asia. *Antimicrob Agents Chemother* 64:e01974–19. <https://doi.org/10.1128/AAC.01974-19>
- Reddy EA, Shaw AV, Crump JA. 2010. Community-acquired bloodstream infections in Africa: a systematic review and meta-analysis. *Lancet Infect Dis* 10:417–432. [https://doi.org/10.1016/S1473-3099\(10\)70072-4](https://doi.org/10.1016/S1473-3099(10)70072-4)
- Huson MAM, Stolp SM, van der Poll T, Grobusch MP. 2014. Community-acquired bacterial bloodstream infections in HIV-infected patients: a systematic review. *Clin Infect Dis* 58:79–92. <https://doi.org/10.1093/cid/cit596>
- Feasey NA, Houston A, Mukaka M, Komrower D, Mwalukomo T, Tenthani L, Jahn A, Moore M, Peters RPH, Gordon MA, Everett DB, French N, van Oosterhout JJ, Allain TJ, Heyderman RS. 2014. A reduction in adult blood

- stream infection and case fatality at a large African hospital following antiretroviral therapy roll-out. *PLoS One* 9:e92226. <https://doi.org/10.1371/journal.pone.0092226>
26. Blanc P, Bonnet F, Leleux O, Perrier A, Bessede E, Pereyre S, Cazanave C, Neau D, Vareil M-O, Lazaro E, Duffau P, Saunier A, André K, Wittkop L, Vandenhende M-A, ANRS CO3 Aquivih-Nouvelle-Aquitaine Cohort Study Group. 2023. Severe bacterial non-AIDS infections in persons with human immunodeficiency virus: the epidemiology and evolution of antibiotic resistance over an 18-year period (2000-2017) in the ANRS CO3 Aquivih-nouvelle-aquitaine cohort. *Clin Infect Dis* 76:1814–1821. <https://doi.org/10.1093/cid/ciac978>
 27. Graham SM. 2010. Nontyphoidal salmonellosis in Africa. *Curr Opin Infect Dis* 23:409–414. <https://doi.org/10.1097/QCO.0b013e32833dd25d>
 28. Mootsikapun P. 2007. Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast of Thailand. *Int J Infect Dis* 11:226–231. <https://doi.org/10.1016/j.ijid.2006.02.010>
 29. Taramasso L, Liggieri F, Cenderello G, Bovis F, Giannini B, Mesini A, Giacomini M, Cassola G, Viscoli C, Di Biagio A. 2019. Bloodstream infections in patients living with HIV in the modern cART era. *Sci Rep* 9:5418. <https://doi.org/10.1038/s41598-019-41829-3>
 30. Ortega M, Almela M, Soriano A, Marco F, Martínez JA, Muñoz A, Peñarroja G, Mensa J. 2008. Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. *Eur J Clin Microbiol Infect Dis* 27:969–976. <https://doi.org/10.1007/s10096-008-0531-5>
 31. Franceschini E, Santoro A, Menozzi M, Bacca E, Venturelli C, Zona S, Bedini A, Digaetano M, Puzzolante C, Meschiari M, Cuomo G, Orlando G, Sarti M, Guaraldi G, Cozzi-Lepri A, Mussini C. 2020. Epidemiology and outcomes of bloodstream infections in HIV-patients during a 13-year period. *Microorganisms* 8:1210. <https://doi.org/10.3390/microorganisms8081210>
 32. Rajasingham R, Williams D, Mehta DB, Meintjes G, Boulware DR, Scriven J. 2014. Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa. *Emerg Infect Dis* 20:722–724. <https://doi.org/10.3201/eid2004.131277>
 33. Lawrence DS, Muthoga C, Mehta DB, Tugume L, Williams D, Rajasingham R, Boulware DR, Mwandumba HC, Moyo M, Dziwani EN, et al. 2022. Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial. *Lancet Glob Health* 10:e1845–e1854. [https://doi.org/10.1016/S2214-109X\(22\)00450-8](https://doi.org/10.1016/S2214-109X(22)00450-8)
 34. Taramasso L, Tattarelli P, Di Biagio A. 2016. Bloodstream infections in HIV-infected patients. *Virulence* 7:320–328. <https://doi.org/10.1080/21505594.2016.1158359>
 35. Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang L-Y, Chow S-C, Morpeth SC, Reyburn H, Njau BN, Shaw AV, Diefenthal HC, Shao JF, Bartlett JA, Maro VP. 2011. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. *Clin Infect Dis* 52:341–348. <https://doi.org/10.1093/cid/ciq103>
 36. Archibald LK, McDonald LC, Rheapumikankit S, Tansuphaswadikul S, Chaovanich A, Eampokalap B, Banerjee SN, Reller LB, Jarvis WR. 1999. Fever and human immunodeficiency virus infection as sentinels for emerging mycobacterial and fungal bloodstream infections in hospitalized patients ≥15 years old, Bangkok. *J Infect Dis* 180:87–92. <https://doi.org/10.1086/314836>
 37. Archibald LK, den Dulk MO, Pallangyo KJ, Reller LB. 1998. Fatal *Mycobacterium tuberculosis* bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania. *Clin Infect Dis* 26:290–296. <https://doi.org/10.1086/516297>
 38. Nguyen H, Nguyen D, Ly V, Dang K, Trinh P, Pham T, Dung N, Lan N, Na D, Vinh N, Lan N, Dat V, Doorn H, Le T. Histoplasmosis in advanced HIV disease: a multi-center prospective diagnostic validation study (895). CROI Conference (Denver, Colorado). <https://www.croiconference.org/abstract/histoplasmosis-in-advanced-hiv-disease-a-multi-center-prospective-diagnostic-validation-study>
 39. Kiertburanakul S, Watcharatipagorn S, Chongtrakool P, Santanirand P. 2012. Epidemiology of bloodstream infections and predictive factors of mortality among HIV-infected adult patients in Thailand in the era of highly active antiretroviral therapy. *Jpn J Infect Dis* 65:28–32.
 40. Torres-Tortosa M, Canueto J, Bascaña A, Vergara A, Sánchez-Porto A, Moreno-Maqueda I, López-Suárez A, González-Serrano M, Cruz E. 2002. Prognostic evaluation of bacteremia and fungemia in patients with acquired immunodeficiency syndrome. *Eur J Clin Microbiol Infect Dis* 21:262–268. <https://doi.org/10.1007/s10096-002-0700-x>
 41. Govender NP, Todd J, Nel J, Mer M, Karstaedt A, Cohen C, for GERMS-SA1. 2021. HIV infection as risk factor for death among hospitalized persons with candidemia, South Africa, 2012-2017. *Emerg Infect Dis* 27:1607–1615. <https://doi.org/10.3201/eid2706.210128>
 42. Wake RM, Govender NP, Omar T, Nel C, Mazanderani AH, Karat AS, Ismail NA, Tiemessen CT, Jarvis JN, Harrison TS. 2020. Cryptococcal-related mortality despite fluconazole preemptive treatment in a cryptococcal antigen screen-and-treat program. *Clin Infect Dis* 70:1683–1690. <https://doi.org/10.1093/cid/ciz485>
 43. Teerawattanasook N, Tauran PM, Teparrukkul P, Wuthiekanun V, Dance DAB, Arif M, Limmathurotsakul D. 2017. Capacity and utilization of blood culture in two referral hospitals in Indonesia and Thailand. *Am J Trop Med Hyg* 97:1257–1261. <https://doi.org/10.4269/ajtmh.17-0193>
 44. Collins S, Cross JH, Ogueji IA, Baraka J, Mwaniki H, Salim N, Ezeaka C, Macharia WM, Chiume M, Aluvaala J, Bohne C, Shamba D, Tillya R, Steege R, Jenkins G, Molyneux EM, Kawaza K, Lawn JE. 2023. Infection detection gap: barriers and enablers to performing blood culture for neonatal inpatients in Kenya, Malawi, Tanzania, and Nigeria. *Arch Dis Child* 108:A167. <https://doi.org/10.1136/archdischild-2023-rcpch.268>
 45. Antillon M, Saad NJ, Baker S, Pollard AJ, Pitzer VE. 2018. The relationship between blood sample volume and diagnostic sensitivity of blood culture for typhoid and paratyphoid fever: a systematic review and meta-analysis. *J Infect Dis* 218:S255–S267. <https://doi.org/10.1093/infdis/jiy471>
 46. World Health Organization. 2015. Global antimicrobial resistance surveillance system: manual for early implementation. World Health Organization, Geneva. <https://iris.who.int/handle/10665/188783>
 47. Archibald LK, Reller LB. 2001. Clinical microbiology in developing countries. *Emerg Infect Dis* 7:302–305. <https://doi.org/10.3201/eid0702.010232>
 48. Blanco JR, Oteo JA, Martínez V, Ramalle E, García A, Ibarra V, Rosel L. 1999. Seroepidemiology of *Bartonella henselae* infection in HIV-infected patients. *Enferm Infecc Microbiol Clin* 17:434–438.
 49. Trataris AN, Rossouw J, Arntzen L, Karstaedt A, Frean J. 2012. *Bartonella* spp. in human and animal populations in Gauteng, South Africa, from 2007 to 2009. *Onderstepoort J Vet Res* 79:452. <https://doi.org/10.4102/ojvr.v79i2.452>
 50. Pons I, Sanfeliu I, Nogueras MM, Sala M, Cervantes M, Amengual MJ, Segura F. 2008. Seroprevalence of *Bartonella* spp. infection in HIV patients in Catalonia, Spain. *BMC Infect Dis* 8:58. <https://doi.org/10.1186/1471-2334-8-58>
 51. Moore CC, Jacob ST, Banura P, Zhang J, Stroup S, Boulware DR, Scheld WM, Houpt ER, Liu J. 2019. Etiology of sepsis in Uganda using a quantitative polymerase chain reaction-based Taqman array card. *Clin Infect Dis* 68:266–272. <https://doi.org/10.1093/cid/ciy472>
 52. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, Aiken AM, Kranzer K. 2021. The association between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. *Clin Microbiol Infect* 27:846–853. <https://doi.org/10.1016/j.cmi.2021.03.026>
 53. World Health Organization. 2017. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. World Health Organization, Geneva, Switzerland
 54. Lebelonyane R, Mills LA, Mogorosi C, Ussery F, Marukutira T, Theu J, Kapanda M, Matambo S, Block L, Raizes E, Makhema J, Lockman S, Bachanas P, Moore J, Jarvis JN. 2020. Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes. *AIDS* 34:2223–2230. <https://doi.org/10.1097/QAD.0000000000002627>